The role of taxanes in the treatment of metastatic melanoma
The role of taxanes in the treatment of metastatic melanoma
复制标题
DOI：
10.1097/00008390-200410000-00013
复制
发表时间：
2004-10-01
影响因子：
2.2
通讯作者：
Bedikian, AY
中科院分区：
文献类型：
--
作者：
Gogas, H;Bafaloukos, D;Bedikian, AY
转移性恶性黑色素瘤患者的治疗仍然很困难。传统化疗的效果令人失望。达卡巴嗪（DTIC）被认为是最有效的单药之一，反应率约为15-20%。许多最初对治疗有反应的患者随后复发。显然，需要改进，对新药物的评估是有必要的。本文回顾了目前转移性黑色素瘤患者单药紫杉烷及其联合治疗的II期研究，并探讨了紫杉烷对治疗策略的可能影响。单药紫杉烷的II期试验有效率从3.3%到17%不等。观察到疾病控制持续时间较长。紫杉烷与DTIC、替莫唑胺、顺铂、卡铂和他莫昔芬联合治疗的有效率从12%到41%不等，这表明它们至少与其他各种联合治疗方案一样有效。在二线转移性肿瘤中已经产生了令人鼓舞的结果。紫杉烷类药物，无论是单独使用还是联合使用，都可能是一些转移性黑色素瘤患者的治疗选择，特别是在二线治疗中。(C) 2004利平科特·威廉姆斯·威尔金斯。
The management of patients with metastatic malignant melanoma remains difficult. Conventional chemotherapy has been disappointingly ineffective. Dacarbazine (DTIC) is considered to be one of the most active single agents with a response rate of approximately 15-20%. Many patients who initially respond to treatment subsequently relapse. Clearly, there is a need for improvement, and the evaluation of new agents is warranted. This article reviews current phase II studies of single-agent taxanes and their combinations in patients with metastatic melanoma, and examines the likely impact of taxanes on treatment strategies. Response rates from phase II trials with single-agent taxanes vary from 3.3% to 17%. Prolonged durations of disease control are observed. Combinations of taxanes with DTIC, temozolomide, cisplatin, carboplatin and tamoxifen have demonstrated response rates from 12% to 41%, suggesting that they are at least as effective as various other combination regimens. Encouraging results have been produced in the second-line metastatic setting. Taxanes, both as single agents and in combinations, may be a treatment option for some patients with metastatic melanoma, especially in the second-line setting. (C) 2004 Lippincott Williams Wilkins.